Caris Life Sciences (CAI) announced a partnership with Everlywell, a digital health company. Caris and Everlywell are partnering to launch Caris Detect, Caris’ forthcoming Multi-Cancer Early Detection blood-based screening assay, through Everlywell’s platform. Caris Detect utilizes comprehensive whole genome sequencing technology to identify multiple cancer types by analyzing molecular signals circulating in the bloodstream. Caris expects to launch the Caris Detect assay in the first half of 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target lowered to $38 from $40 at Evercore ISI
- Caris Life Sciences price target raised to $30 from $28 at Canaccord
- BLSH, SLMT, CAI: Cathie Wood Loads Up on Crypto and Healthcare Stocks, Trims a Consumer Tech Name
- Caris Life Sciences partners with Roche’s Genentechh for cancer targets
- Caris Life Sciences price target lowered to $35 from $39 at BofA